000310360 001__ 310360
000310360 005__ 20260311121051.0
000310360 0247_ $$2doi$$a10.1002/ijc.70397
000310360 0247_ $$2pmid$$apmid:41792052
000310360 0247_ $$2ISSN$$a0020-7136
000310360 0247_ $$2ISSN$$a1097-0215
000310360 037__ $$aDKFZ-2026-00556
000310360 041__ $$aEnglish
000310360 082__ $$a610
000310360 1001_ $$aFasching, Peter A$$b0
000310360 245__ $$aReal-world progression-free survival and overall survival in patients with HR+/HER2- advanced breast cancer treated in first-line with ribociclib, endocrine monotherapy or chemotherapy: Results from the observational RIBANNA study.
000310360 260__ $$aBognor Regis$$bWiley-Liss$$c2026
000310360 3367_ $$2DRIVER$$aarticle
000310360 3367_ $$2DataCite$$aOutput Types/Journal article
000310360 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1773225405_3298573
000310360 3367_ $$2BibTeX$$aARTICLE
000310360 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000310360 3367_ $$00$$2EndNote$$aJournal Article
000310360 500__ $$a#NCTZFB9# / epub
000310360 520__ $$aCyclin-dependent kinase 4 and 6 inhibitors (CDK4/6i) combined with endocrine therapy are the preferred choice for first-line treatment of patients with HR+/HER2- locally advanced/metastatic breast cancer (aBC). The CDK4/6i ribociclib in combination with an aromatase inhibitor (AI) or fulvestrant (FUL) has demonstrated significant progression-free survival (PFS) and overall survival (OS) benefits for pre- and postmenopausal aBC patients who were enrolled in the three pivotal MONALEESA trials. Following the initial approval of ribociclib in 2017, the non-interventional RIBANNA study was initiated to evaluate the effectiveness and safety of ribociclib plus AI/FUL therapy among patients with aBC in a real-world setting. Two additional treatment cohorts (endocrine monotherapy [ET] and chemotherapy [CT]) were included to extend the knowledge about current aBC treatments. A total of 2567 patients were enrolled in 279 study centers, of whom 1852 were treated with ribociclib+AI/FUL, 183 were treated with ET, and 139 were treated with CT, who were available for effectiveness analyses. Median PFS (mPFS) and median OS (mOS) on first-line treatment with ribociclib+AI/FUL were 35.0 and 76.0 months, respectively. Adjustment for differences in demographic and baseline characteristics resulted in a longer mPFS on ribociclib+AI/FUL (34.7 months) compared to ET (26.4 months) or CT (19.2 months). Adverse events (AEs) on ribociclib were consistent with those seen in the pivotal trials, and no new safety signals were observed. The RIBANNA study confirmed the PFS and OS benefit seen in the MONALEESA trials. Together with the safety data, this large real-world dataset supports the favorable risk/benefit profile of ribociclib in large scale patient populations.
000310360 536__ $$0G:(DE-HGF)POF4-899$$a899 - ohne Topic (POF4-899)$$cPOF4-899$$fPOF IV$$x0
000310360 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
000310360 650_7 $$2Other$$aCDK4/6 inhibitors
000310360 650_7 $$2Other$$ametastatic breast cancer
000310360 650_7 $$2Other$$aobservational study
000310360 650_7 $$2Other$$aoverall survival
000310360 650_7 $$2Other$$aribociclib
000310360 7001_ $$aBrucker, Cosima$$b1
000310360 7001_ $$00000-0003-3814-8775$$aDecker, Thomas$$b2
000310360 7001_ $$aEngel, Anne$$b3
000310360 7001_ $$aGöhler, Thomas$$b4
000310360 7001_ $$aJackisch, Christian$$b5
000310360 7001_ $$aJanssen, Jan$$b6
000310360 7001_ $$aKöhler, Andreas$$b7
000310360 7001_ $$aLüdtke-Heckenkamp, Kerstin$$b8
000310360 7001_ $$aLüftner, Diana$$b9
000310360 7001_ $$aMarmé, Frederik$$b10
000310360 7001_ $$avan Mackelenbergh, Marion$$b11
000310360 7001_ $$aRautenberg, Beate$$b12
000310360 7001_ $$aSchmidt, Marcus$$b13
000310360 7001_ $$aWeide, Rudolf$$b14
000310360 7001_ $$0P:(DE-HGF)0$$aWimberger, Pauline$$b15
000310360 7001_ $$aKisseleff, Elena$$b16
000310360 7001_ $$aPfister, Christina$$b17
000310360 7001_ $$aQuiering, Claudia$$b18
000310360 7001_ $$aRoos, Christian$$b19
000310360 7001_ $$aWöckel, Achim$$b20
000310360 773__ $$0PERI:(DE-600)1474822-8$$a10.1002/ijc.70397$$gp. ijc.70397$$pnn$$tInternational journal of cancer$$vnn$$x0020-7136$$y2026
000310360 909CO $$ooai:inrepo02.dkfz.de:310360$$pVDB
000310360 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b15$$kDKFZ
000310360 9131_ $$0G:(DE-HGF)POF4-899$$1G:(DE-HGF)POF4-890$$2G:(DE-HGF)POF4-800$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bProgrammungebundene Forschung$$lohne Programm$$vohne Topic$$x0
000310360 9141_ $$y2026
000310360 915__ $$0StatID:(DE-HGF)0420$$2StatID$$aNationallizenz$$d2025-11-11$$wger
000310360 915__ $$0StatID:(DE-HGF)3001$$2StatID$$aDEAL Wiley$$d2025-11-11$$wger
000310360 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bINT J CANCER : 2022$$d2025-11-11
000310360 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2025-11-11
000310360 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2025-11-11
000310360 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2025-11-11
000310360 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2025-11-11
000310360 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2025-11-11
000310360 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2025-11-11
000310360 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2025-11-11
000310360 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences$$d2025-11-11
000310360 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2025-11-11
000310360 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bINT J CANCER : 2022$$d2025-11-11
000310360 9201_ $$0I:(DE-He78)DD04-20160331$$kDD04$$lKoordinierungsstelle NCT Dresden$$x0
000310360 980__ $$ajournal
000310360 980__ $$aVDB
000310360 980__ $$aI:(DE-He78)DD04-20160331
000310360 980__ $$aUNRESTRICTED